Author: Editor

Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.

Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation and acquired resistance that does not harbor a T790M mutation.

W. Kimryn Rathmell, MD, PhD of Vanderbilt Ingram Cancer Center discusses Novel epigenetic targeting approaches at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Laurence Albiges, Gustave Roussy Villejuif, France discusses HIF-2aa new target in metastatic RCCat the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Toni K. Choueiri MD of Dana Farber discusses Randomised phase 2 study of sapanisertib (TAK?228/MLN0128) ± TAK-117 versus everolimus in patients with VEGF-targeted therapy-refractory metastatic clear cell renal cell carcinoma at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Philip Zeuschner, MD of Universität des Saarlandes, Saarbrücken (UKS) discusses Learning curves in 500 robot-assisted partial nephrectomies: the bed-side assistant counts at the Kidney Cancer Associations International Symposium 2019 in Dubrovnik, Croatia

Toni K. Choueiri, MD of Dana-Farber Cancer Institute, Boston, MA discusses A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced RCCat the Kidney Cancer Association International Symposium in Dubrovnik, Croatia

Prof. Alessandro VOLPE University of Eastern Piedmont Maggiore della Carità Hospital, Novara, Italy discusses SMALL RENAL MASSES NON SURGICAL MANAGEMENT at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Manuela Schmidinger, MD, Camillo Porta, MD, Romano Danesi, MD, PhD, Brian I. Rini, MD discuss Optimising advanced RCC treatment: the place of Fotivda®?(tivozanib) in 2019 and beyond at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Dr Emmanuel MEYER Department of radiation oncology Centre Fran̤ois Baclesse Caen РFrance discusses Oligometastatic disease: Localized vs systemic therapy Non-surgical local management of RCC at the Kidney Cancer Associations International Symposium 2019 in Dubrovnik, Croatia

Fernando Gómez Muñoz. MD PhD Vascular and Interventional Radiology Hospital Clinic de Barcelona Hospital Sant Joan de Deu, Barcelona Netherlands Kanker Instituut, Amsterdam dicusses Ablative Therapies Versus Surgery: How the Evidence May Be Improved? at the Kidney Cancer Association International Symposium

Stereotactic Ablative Body RadioTherapy in Kidney Cancer Ben Vanneste, MD, PhD Radiation-Oncologist, MAASTRO Clinic, The Netherlands discusses Stereotactic Ablative Body RadioTherapy in Kidney Cancer at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Dr Kevin Litchfield Kevin.litchfield@crick.ac.uk Twitter: @kevlitchfield discusses Genomic and Transcriptomic Biomarkers of IO Response in RCC at the Kidney Cancer International Symposium 2019 in Dubrovnik, Croatia

Grant D Stewart, MD Surgical Oncology Lead, University Lecturer, University of Cambridge Consultant Urological Surgeon, Addenbrookes Hospital discusses Adjuvant immuno-oncology trials update at the Kidney Cancer International Symposium 2019 in Dubrovnik, Croatia

Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.

Drs. Ben Solomon, Leora Horn, & Jack West evaluate the merits of broad genetic testing with a “next generation sequencing” platform compared to selective, limited testing for the most proven driver mutations in patients with advanced NSCLC.

Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among the second generation ALK inhibitors that would lead to a reason to prefer one over another for a particular patient.

Drs. Leora Horn, Ben Solomon, & Jack West review whether there are specific factors that should make one second generation ALK inhibitor more ideal than other competing options for a specific patient with an ALK rearrangement.

Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.

Dr. Karen Reckamp of City of Hope Cancer Center reviews the concept of acquired resistance to targeted therapies in patients with a driver mutation and why it occurs.

Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of “pseudoprogression”.

Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.

Drs. Ben Solomon, Leora Horn, & Jack West discuss whether the data highlighting cognitive deficits from whole brain radiation therapy (WBRT) for patients with brain metastases should change our recommendations for prophylactic cranial irradiation (PCI).

Drs. Ben Solomon, Leora Horn, & Jack West review impressive data demonstrating a striking survival improvement from successful efforts at smoking cessation among smokers undergoing lung cancer CT screening.

Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.

James Larkin of the The Royal Marsden NHS Foundation Trust pays tribute to his friend and legendary oncologist Martin Gore at the Kidney Cancer International Symposium 2019 in Dubrovnik, Croatia

Thomas Powles Director of Barts Cancer Center. Professor of Urology Cancer, Barts Cancer Institute discusses firist line clear cell RCC: All change at the Kidney Cancer International Symposium 2019 in Dubrovnik, Croatia

W. Kimryn Rathmell, MD, PhD Director of the Division of Hematology and Oncology Vanderbilt University Medical Center discusses Endogenous retrovirus and immune response in RCC at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Samra Turajlic, MD The Royal Marsden NHS Foundation Trust outlines Cell-free tumour DNA (cfDNA) detection in advanced renal cell carcinoma at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Christopher Wood, MD MD Anderson Cancer Center expresses his thoughts on the late Martin Gore at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

David Quinn, MD USC Norris Comprehensive Cancer Center gives a heartfelt tribute to Dr. Martin Gore and his US/International Perspective at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Bernard Escudier of the Institut Gustave Roussy in Villejuif, France reminisces about his late friend Martin Gore at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Tobias Klatte, MD, PhD, FEBU, FRCS(Ed) Consultant Urological Surgeon, Royal Bournemouth Hospital Visiting Researcher, University of Cambridge Honorary Lecturer, University of Edinburgh asks the question “Molecular biomarker for cytoreductive nephrectomy?” at the Kidney Cancer International Symposium 2019 in Dubrovnik, Croatia

This presentation aims to provide an overview of the mRCC patient journey and the challenges clinicians face. To explore how clinical decisions are taken today and the factors that affect our current choices. To examine the emerging role of IO combinations in mRCC management, and discuss our future patient selection dilemmas and unanswered questions. From the Kidney Cancer Association International Symposium 2019 in Dubrovnik

John B. Haanen MD PhD Department of Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital asks the question “Do we need a new Carmena in the IO era?”at the Kidney Cancer Association International Symposium in Dubrovnick 2019.

Andy Thomas from Kidney Cancer Support Network discusses Cytoreductive Nephrectomy Patient Perspective at the Kidney Cancer Association International Symposium in Dubrovnik 2019

Oncoceutics Expands Patent Family to Include Composition of Matter for ONC206 in Europe  Philadelphia, PA (March 4, 2019) – Oncoceutics, Inc. announced that the European Patent Office (EPO) has issued EP 3,068,401 entitled “7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Use” with an expiration date of September 12, 2034.  This patent covers the composition of matter for ONC206, its di-salt formulation, and its use in the treatment of cancer.  ONC206, a member of the imipridone family of anti-cancer small molecules, has demonstrated anti-cancer activity and safety in preclinical models and is planned to enter the clinic in 2019. These patents pave the path for…

Axel Bex Royal Free London NHS Foundation Trust, UCL Division of Surgical and Interventional Science, London, UK and The Netherlands Cancer Institute, Amsterdam, Netherlands discusses “No nephrectomy versus deferred nephrectomy” at the Kidney Cancer Association International Symposium in Dubrovnik 2019

Michael Staehler, M.D. Ph.D. Head Interdisciplinary Center on Renal Tumors Department of Urology University of Munich, Germany takes the PROCytoreductive Nephrectomy in Kidney Cancer at the Kidney Cancer Association International Symposium in Dubrovnik 2019

Lorenzo Marconi, MD, FEBU Coimbra, Portugal discusses Clinical Marker for Cytoreductive Nephrectomy? at the Kidney Cancer International Symposium in Dubrovnik 2019.

John B. Haanen MD PhD gives the Fitzpatrick Memorial Lecture entitled Do we need a new Carmena in the IO era?

Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a “liquid biopsy” option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.

Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.

Dr. West moderates a question & answer session with Drs. Leora Horn and Greg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.

Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.

Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.

The brain is a common site of disease in patients with ALK+ lung cancer. In this video, Dr. Horn illustrates the line-up of ALK+ treatments and how they work breaking through the blood/brain barrier.

Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for ALK+ and ROS1 patients.